{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 65 of 122', 'addition, the effect of peanut OIT on the immune system of the mother and fetus during', 'pregnancy is unknown. Therefore, all female subjects of childbearing potential must have a', 'negative serum pregnancy test before the first dose of study product and a negative urine test', 'during the treatment period and must avoid pregnancy during the study.', 'All postmenarchal female subjects will be provided with age-appropriate counseling and', 'information about contraception per the standard of care at the study site. The information', 'should include adequate information about the use, effectiveness, and side-effects of', 'contraceptive methods, and be conducted in as private a setting as possible using a sensitive,', 'patient-centered approach. Sexually active females of childbearing potential will be required', 'to use one of the following types of contraception:', 'A highly effective method of birth control, defined as one that results in a low failure', 'rate (ie, < 1% per year) when used consistently and correctly, as follows:', '-', 'Combined (estrogen- and progestogen-containing) hormonal contraception', 'associated with inhibition of ovulation (oral, intravaginal, or transdermal).', '-', 'Progestogen-only hormonal contraception associated with inhibition of ovulation', '(oral, injectable, or implantable).', '-', 'Intrauterine device (IUD).', '-', 'Intrauterine hormone-releasing system (IUS).', '-', 'Bilateral tubal occlusion.', '-', 'Vasectomized partner.', '-', 'Sexual abstinence.', 'If a highly effective single method of birth control is not used, an effective,', 'double-barrier method of contraception should be used (eg, male condom in', 'conjunction with a cervical cap, diaphragm, or contraceptive sponge with', 'spermicide).', 'Where local requirements are more stringent, a highly effective method of birth control must', 'be used.', 'Females of childbearing potential are defined as all women physiologically capable of', 'becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes', 'intercourse with a male partner and women whose partners have been sterilized by', 'vasectomy or other means, unless they meet the following criteria: at least 12 months of', 'natural (spontaneous) amenorrhea, 6 months of spontaneous amenorrhea with serum follicle', 'stimulating hormone (FSH) levels > 40 IU/L, or at least 6 weeks after surgical bilateral', 'oophorectomy with or without hysterectomy or hysterectomy.', '8.6', 'Adverse Event Reporting', 'Safety reporting to regulatory authorities will be implemented according to global and', 'country-specific regulations.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 66 of 122', 'To elicit adverse event reports from subjects, the study site personnel should question the', 'subject and parent/caregiver in a general way without suggesting specific symptoms.', 'Adverse events may be identified during study visits.', 'All signs and symptoms associated with an adverse event, whether or not related to the study', 'product, must be fully and completely documented for all subjects (ie, both treatment', \"groups) on the adverse event case report form and in the subject's source documents.\", 'In addition, any adverse event resulting in permanent treatment discontinuation must be', \"recorded on the appropriate case report form, as well as documented in the subject's source\", 'documents.', 'Adverse event terms should include a diagnosis, as available, and is preferred to listing all', 'the individual signs and symptoms. If the diagnosis is not known, the investigator is to', 'record each sign and symptom as an individual adverse event. For multiple symptoms of', 'allergic reactions/hypersensitivity, each individual symptom is to be entered separately on the', 'case report forms.', '8.6.1', 'Adverse Event Reporting Period', 'Collection and reporting of adverse event information will begin at the time the screening', 'informed consent/assent form is signed and will continue for all subjects through early', 'discontinuation or study exit (Figure 4). Adverse event reporting and follow-up will continue', 'after early discontinuation or study exit in the following circumstances:', 'Subjects with ongoing adverse events will have safety follow-up for at least 30 days', 'until the adverse events resolve or stabilize, the subject withdraws consent for', 'follow-up, or the study is terminated.', 'Subjects who have GI adverse events of interest (Section 8.5.6.2) will have safety', 'follow-up for 6 months or until chronic or recurrent GI symptoms resolve or stabilize,', 'whichever is last.', 'Figure 4: Adverse Event Reporting Period', 'Adverse event reporting', 'Signed', 'informed', 'Study', 'Early Discontinuation /', 'Safety', 'Screening', 'Treatment', 'consent', 'Study Exit', 'Follow-Up [1]', 'Pretreatment-emergent', 'Treatment-emergent', 'adverse events', 'adverse events', '[1] Subjects with unresolved adverse events or gastrointestinal adverse events of interest at early', 'discontinuation or study exit will have safety follow-up.']\n\n###\n\n", "completion": "END"}